financetom
Business
financetom
/
Business
/
SoftBank books surprise loss of $2.4 billion in third quarter
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SoftBank books surprise loss of $2.4 billion in third quarter
Feb 11, 2025 11:17 PM

TOKYO, Feb 12 (Reuters) - Japanese technology investor

SoftBank Group booked a surprising net loss of 369.2

billion yen ($2.4 billion) in the October-December quarter as

valuations at its Vision Fund investment arm fell.

In particular, SoftBank was hit by unrealised valuation

losses for South Korean e-commerce platform Coupang ( CPNG ),

Chinese ride-hailing firm Didi Global and AutoStore Holdings

.

The result will further raise questions about how SoftBank

will fund one of its most ambitious undertakings - a hefty

investment in OpenAI.

Cash and cash equivalents dropped to 4.7 trillion yen

($30.6 billion) as of end-December from 6.2 trillion yen in

March which was the end of the previous financial year.

Sources said in January that SoftBank was in talks to invest

up to $25 billion in the ChatGPT creator. Recent media reports

have said that figure has grown to $40 billion though some of

that amount would later be syndicated out to other investors.

SoftBank has also committed to investing $15 billion in

Stargate - a venture with OpenAI and Oracle that will

build AI data centre capacity in the United States and which has

been backed by U.S. President Donald Trump.

The announcements mark a return to the aggressive SoftBank

of old which rocked the technology investment world by taking

big bets on startups through its Vision Funds.

The third-quarter result compares to an LSEG consensus

estimate of a net profit of 234 billion yen drawn from four

analysts and a profit of 950 billion yen in the same period a

year earlier.

The Vision Fund unit posted an investment loss of 352.7

billion yen, breaking a run of two consecutive quarters in the

black.

Vision Fund 1 has had a gross gain of $21.6 billion since

its inception in 2017 while Vision Fund 2, which covers a broad

suite of earlier-stage startups, has logged a $22.2 billion loss

since 2019.

($1 = 153.6000 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- Verastem Oncology (VSTM) late Thursday reported that an ongoing phase 1/2 clinical trial evaluating avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in 41 patients with metastatic pancreatic cancer reached an interim partial response rate of 83%. Of 26 patients in all the trial cohorts who have had their first scan while...
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
E3 Lithium Narrows Q1 Loss; Company Hasn't Started Commercial Production or Generated Cash Flow
May 24, 2024
08:25 AM EDT, 05/24/2024 (MT Newswires) -- E3 Lithium ( EEMMF ) on Friday reported a narrower loss for the first quarter even though the company has not generated revenues from operations and had an accumulated deficit of $45.2 million at the end of March. The company reported a first-quarter net loss of $2.4 million, or $0.03 per share, compared...
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
--Cato Keeps Quarterly Dividend at $0.17 per share, Payable June 24 to Shareholders of Record June 10
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Price: 5.73, Change: -0.05, Percent Change: -0.87 ...
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
Organon, Henlius' Denosumab Biosimilar HLX14 Gets European Validation
May 24, 2024
08:17 AM EDT, 05/24/2024 (MT Newswires) -- Organon (OGN) and Shanghai Henlius Biotech said Friday their marketing authorization applications for HLX14, a denosumab biosimilar, have been validated by the European Medicines Agency. The submissions were based on a phase 3 study comparing HLX14 with denosumab in postmenopausal women with osteoporosis, the companies said. Henlius licensed HLX14 to Organon in 2022...
Copyright 2023-2025 - www.financetom.com All Rights Reserved